Yue Xuetian, Zhang Cen, Zhao Yuhan, Liu Juan, Lin Alan W, Tan Victor M, Drake Justin M, Liu Lianxin, Boateng Michael N, Li Jun, Feng Zhaohui, Hu Wenwei
Rutgers Cancer Institute of New Jersey, the State University of New Jersey, New Brunswick, New Jersey 08903, USA.
Department of Radiation Oncology, the State University of New Jersey, New Brunswick, New Jersey 08903, USA.
Genes Dev. 2017 Aug 15;31(16):1641-1654. doi: 10.1101/gad.301564.117.
Tumor suppressor p53 is frequently mutated in human cancer. Mutant p53 often promotes tumor progression through gain-of-function (GOF) mechanisms. However, the mechanisms underlying mutant p53 GOF are not well understood. In this study, we found that mutant p53 activates small GTPase Rac1 as a critical mechanism for mutant p53 GOF to promote tumor progression. Mechanistically, mutant p53 interacts with Rac1 and inhibits its interaction with SUMO-specific protease 1 (SENP1), which in turn inhibits SENP1-mediated de-SUMOylation of Rac1 to activate Rac1. Targeting Rac1 signaling by RNAi, expression of the dominant-negative Rac1 (Rac1 DN), or the specific Rac1 inhibitor NSC23766 greatly inhibits mutant p53 GOF in promoting tumor growth and metastasis. Furthermore, mutant p53 expression is associated with enhanced Rac1 activity in clinical tumor samples. These results uncover a new mechanism for Rac1 activation in tumors and, most importantly, reveal that activation of Rac1 is an unidentified and critical mechanism for mutant p53 GOF in tumorigenesis, which could be targeted for therapy in tumors containing mutant p53.
肿瘤抑制因子p53在人类癌症中经常发生突变。突变型p53通常通过功能获得(GOF)机制促进肿瘤进展。然而,突变型p53 GOF的潜在机制尚不清楚。在本研究中,我们发现突变型p53激活小GTP酶Rac1是突变型p53 GOF促进肿瘤进展的关键机制。从机制上讲,突变型p53与Rac1相互作用并抑制其与SUMO特异性蛋白酶1(SENP1)的相互作用,这反过来又抑制了SENP1介导的Rac1去SUMO化以激活Rac1。通过RNA干扰靶向Rac1信号、表达显性负性Rac1(Rac1 DN)或特异性Rac1抑制剂NSC23766可极大地抑制突变型p53 GOF在促进肿瘤生长和转移方面的作用。此外,在临床肿瘤样本中,突变型p53的表达与增强的Rac1活性相关。这些结果揭示了肿瘤中Rac1激活的新机制,最重要的是,揭示了Rac1激活是突变型p53在肿瘤发生过程中GOF的一个尚未明确的关键机制,这可能成为含有突变型p53肿瘤治疗的靶点。